Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial
Authors' conclusion
The peak amount of weight loss expected following initiation of semaglutide cannot be predicted based on clinically available baseline characteristics; unmeasured biological, behavioral, or genetic differences are likely responsible for variability in individual response. Women treated with the highest dose of semaglutide experienced the largest %BWL.
Study context
- Population
- Adults (mean age 62, 72% men) with obesity and preexisting atherosclerotic disease without diabetes, randomized to semaglutide in SELECT and continuing treatment ≥1 year86.3% of semaglutide-randomized
- Participants
- 7,594 adults
- Primary endpoint
- Peak percentage body weight loss (%BWL) and its prediction by clinically available baseline characteristics
Methodological detailsprespecified analysis, general linear model estimated with ordinary least squares
- Prespecified analysis
- General linear model estimated with ordinary least squares
Primary result
As reported in the abstract
Peak %BWL · median 19 months (IQR 10-30) of treatment
Semaglutide
12.5
median · IQR 7.9–17.9 · %
Further findings
| Outcome | Values |
|---|---|
| Peak %BWL by maximum semaglutide dose | 0.24 mg median 6.0 (IQR 1.9–10.9) % · 2.4 mg median 13.3 (IQR 9.0–18.4) % |
| Peak %BWL by sex | Women median 16.6 (IQR 10.9–23.4) % · Men median 12.4 (IQR 8.4–16.9) % |
Peak %BWL by maximum semaglutide dose
- Semaglutide dose was associated with peak %BWL
Original publication
Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial. Diabetes Care. Published 24 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →